Skip to main content
Erschienen in: Journal of Thrombosis and Thrombolysis 2/2018

31.05.2018

A pulmonary embolism response team (PERT) approach: initial experience from the Cleveland Clinic

verfasst von: Jamal H. Mahar, Ihab Haddadin, Divyajot Sadana, Abishek Gadre, Natalie Evans, Deborah Hornacek, Natalia Fendrikova Mahlay, Marcelo Gomes, Douglas Joseph, Maya Serhal, Michael Zhen-Yu Tong, Seth R. Bauer, Michael Militello, Bernard Silver, Mehdi Shishehbor, John R. Bartholomew, Gustavo A. Heresi

Erschienen in: Journal of Thrombosis and Thrombolysis | Ausgabe 2/2018

Einloggen, um Zugang zu erhalten

Abstract

Management of intermediate and high risk acute pulmonary embolism (PE) is challenging. The role of multidisciplinary teams for the care of these patients is emerging. Herein, we report our experience with a pulmonary embolism response team (PERT). We conducted a retrospective chart review on all patients admitted to the Cleveland Clinic main campus who required activation of the (PERT) from October 1, 2014 to September 1, 2016. We extracted data pertaining to clinical presentation, bleeding complications, and pre- and post-discharge imaging. Patients were classified as low, intermediate or high risk PE. Descriptive and continuous variables were collected and analyzed. There were 134 PERT activations. PE was confirmed by CT-PA in 118 patients. Fifteen (13%) patients were classified as low risk, 80 (68%) intermediate risk PE and 23 (19%) high risk PE. Fourteen (12%) patients were treated with catheter directed rtPA, 6 (5%) received full dose (100 mg rtPA), 16 (13%) received systemic half-dose (50 mg rtPA), 6 (5%) underwent a surgical embolectomy and 4 (3%) underwent mechanical thrombectomy. 65 (55%) patients received anticoagulation only, and 8 (7%) patients were managed conservatively without any anticoagulation or advanced therapy. 11 (9%) patients died while during the hospitalization. Fourteen patients had major bleeding events. There were no bleeding events among patients who received systemic low dose or full dose rtPA. A multidisciplinary approach to cases of intermediate risk and high risk PE can be implemented successfully. We saw a relatively low rate of bleeding events with use of rtPA.
Literatur
1.
Zurück zum Zitat Wiener RS, Schwartz LM, Woloshin S (2011) Time trends in pulmonary embolism in the United States: evidence of overdiagnosis. Arch Intern Med 09(9):831–837 171( Wiener RS, Schwartz LM, Woloshin S (2011) Time trends in pulmonary embolism in the United States: evidence of overdiagnosis. Arch Intern Med 09(9):831–837 171(
2.
Zurück zum Zitat Fanikos J, Rao A, Seger AC, Carter D, Piazza G, Goldhaber SZ (2013) Hospital costs of acute pulmonary embolism. Am J Med 126(2):127–132CrossRefPubMed Fanikos J, Rao A, Seger AC, Carter D, Piazza G, Goldhaber SZ (2013) Hospital costs of acute pulmonary embolism. Am J Med 126(2):127–132CrossRefPubMed
3.
Zurück zum Zitat Jaff MR, McMurtry MS, Archer SL, Cushman M, Goldenberg N, Goldhaber SZ et al (2011) Management of massive and submassive pulmonary embolism, iliofemoral deep vein thrombosis, and chronic thromboembolic pulmonary hypertension: a scientific statement from the American Heart Association. Circulation 26(16):1788–1830CrossRef Jaff MR, McMurtry MS, Archer SL, Cushman M, Goldenberg N, Goldhaber SZ et al (2011) Management of massive and submassive pulmonary embolism, iliofemoral deep vein thrombosis, and chronic thromboembolic pulmonary hypertension: a scientific statement from the American Heart Association. Circulation 26(16):1788–1830CrossRef
4.
Zurück zum Zitat Kucher N, Boekstegers P, Muller OJ, Kupatt C, Beyer-Westendorf J, Heitzer T et al (2014) Randomized, controlled trial of ultrasound-assisted catheter-directed thrombolysis for acute intermediate-risk pulmonary embolism. Circulation 129(4):479–486CrossRefPubMed Kucher N, Boekstegers P, Muller OJ, Kupatt C, Beyer-Westendorf J, Heitzer T et al (2014) Randomized, controlled trial of ultrasound-assisted catheter-directed thrombolysis for acute intermediate-risk pulmonary embolism. Circulation 129(4):479–486CrossRefPubMed
5.
Zurück zum Zitat Sharifi M, Bay C, Skrocki L, Rahimi F, Mehdipour M (2013) Moderate pulmonary embolism treated with thrombolysis (from the “MOPETT” Trial). Am J Cardiol 15(2):273–277 111(CrossRef Sharifi M, Bay C, Skrocki L, Rahimi F, Mehdipour M (2013) Moderate pulmonary embolism treated with thrombolysis (from the “MOPETT” Trial). Am J Cardiol 15(2):273–277 111(CrossRef
6.
Zurück zum Zitat Barnes GD, Kabrhel C, Courtney DM, Naydenov S, Wood T, Rosovsky R et al (2016) Diversity in the pulmonary embolism response team model: an organizational survey of the National PERT Consortium Members. Chest 150(6):1414–1417CrossRefPubMed Barnes GD, Kabrhel C, Courtney DM, Naydenov S, Wood T, Rosovsky R et al (2016) Diversity in the pulmonary embolism response team model: an organizational survey of the National PERT Consortium Members. Chest 150(6):1414–1417CrossRefPubMed
7.
Zurück zum Zitat Schulman S, Kearon C (2005) Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non-surgical patients. J Thromb Haemost 3(4):692–694CrossRefPubMed Schulman S, Kearon C (2005) Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non-surgical patients. J Thromb Haemost 3(4):692–694CrossRefPubMed
8.
Zurück zum Zitat Alviar CL, Heresi GA (2016) Thrombolysis in submassive pulmonary embolism: Finding the balance. Cleve Clin J Med 83(12):933–936CrossRefPubMed Alviar CL, Heresi GA (2016) Thrombolysis in submassive pulmonary embolism: Finding the balance. Cleve Clin J Med 83(12):933–936CrossRefPubMed
9.
Zurück zum Zitat Serhal M, Haddadin IS, Heresi GA, Hornacek DA, Shishehbor MH, Bartholomew JR (2017) Pulmonary embolism response teams. J Thromb Thrombolysis 44(1):19–29CrossRefPubMed Serhal M, Haddadin IS, Heresi GA, Hornacek DA, Shishehbor MH, Bartholomew JR (2017) Pulmonary embolism response teams. J Thromb Thrombolysis 44(1):19–29CrossRefPubMed
10.
Zurück zum Zitat Kabrhel C, Rosovsky R, Channick R, Jaff MR, Weinberg I, Sundt T et al (2016) A multidisciplinary pulmonary embolism response team: initial 30-month experience with a novel approach to delivery of care to patients with submassive and massive pulmonary embolism. Chest 150(2):384–393CrossRefPubMed Kabrhel C, Rosovsky R, Channick R, Jaff MR, Weinberg I, Sundt T et al (2016) A multidisciplinary pulmonary embolism response team: initial 30-month experience with a novel approach to delivery of care to patients with submassive and massive pulmonary embolism. Chest 150(2):384–393CrossRefPubMed
11.
Zurück zum Zitat Barnes G, Giri J, Courtney DM, Naydenov S, Wood T, Rosovsky R et al (1995) Nuts and bolts of running a pulmonary embolism response team: results from an organizational survey of the National PERT Consortium members. Hosp Pract 45:76–80CrossRef Barnes G, Giri J, Courtney DM, Naydenov S, Wood T, Rosovsky R et al (1995) Nuts and bolts of running a pulmonary embolism response team: results from an organizational survey of the National PERT Consortium members. Hosp Pract 45:76–80CrossRef
12.
Zurück zum Zitat Aujesky D, Roy PM, Verschuren F, Righini M, Osterwalder J, Egloff M et al (2011) Outpatient versus inpatient treatment for patients with acute pulmonary embolism: an international, open-label, randomised, non-inferiority trial. Lancet 378(9785):41–48CrossRefPubMed Aujesky D, Roy PM, Verschuren F, Righini M, Osterwalder J, Egloff M et al (2011) Outpatient versus inpatient treatment for patients with acute pulmonary embolism: an international, open-label, randomised, non-inferiority trial. Lancet 378(9785):41–48CrossRefPubMed
13.
Zurück zum Zitat Curtis GM, Lam SW, Reddy AJ, Bauer SR (2014) Risk factors associated with bleeding after alteplase administration for pulmonary embolism: a case-control study. Pharmacotherapy 34(8):818–825CrossRefPubMed Curtis GM, Lam SW, Reddy AJ, Bauer SR (2014) Risk factors associated with bleeding after alteplase administration for pulmonary embolism: a case-control study. Pharmacotherapy 34(8):818–825CrossRefPubMed
14.
Zurück zum Zitat Poterucha TJ, Bergmark B, Aranki S, Kaneko T, Piazza G (2015) Surgical Pulmonary embolectomy. Circulation 132(12):1146–1151CrossRefPubMed Poterucha TJ, Bergmark B, Aranki S, Kaneko T, Piazza G (2015) Surgical Pulmonary embolectomy. Circulation 132(12):1146–1151CrossRefPubMed
Metadaten
Titel
A pulmonary embolism response team (PERT) approach: initial experience from the Cleveland Clinic
verfasst von
Jamal H. Mahar
Ihab Haddadin
Divyajot Sadana
Abishek Gadre
Natalie Evans
Deborah Hornacek
Natalia Fendrikova Mahlay
Marcelo Gomes
Douglas Joseph
Maya Serhal
Michael Zhen-Yu Tong
Seth R. Bauer
Michael Militello
Bernard Silver
Mehdi Shishehbor
John R. Bartholomew
Gustavo A. Heresi
Publikationsdatum
31.05.2018
Verlag
Springer US
Erschienen in
Journal of Thrombosis and Thrombolysis / Ausgabe 2/2018
Print ISSN: 0929-5305
Elektronische ISSN: 1573-742X
DOI
https://doi.org/10.1007/s11239-018-1686-2

Weitere Artikel der Ausgabe 2/2018

Journal of Thrombosis and Thrombolysis 2/2018 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Erhebliches Risiko für Kehlkopfkrebs bei mäßiger Dysplasie

29.05.2024 Larynxkarzinom Nachrichten

Fast ein Viertel der Personen mit mäßig dysplastischen Stimmlippenläsionen entwickelt einen Kehlkopftumor. Solche Personen benötigen daher eine besonders enge ärztliche Überwachung.

Nach Herzinfarkt mit Typ-1-Diabetes schlechtere Karten als mit Typ 2?

29.05.2024 Herzinfarkt Nachrichten

Bei Menschen mit Typ-2-Diabetes sind die Chancen, einen Myokardinfarkt zu überleben, in den letzten 15 Jahren deutlich gestiegen – nicht jedoch bei Betroffenen mit Typ 1.

15% bedauern gewählte Blasenkrebs-Therapie

29.05.2024 Urothelkarzinom Nachrichten

Ob Patienten und Patientinnen mit neu diagnostiziertem Blasenkrebs ein Jahr später Bedauern über die Therapieentscheidung empfinden, wird einer Studie aus England zufolge von der Radikalität und dem Erfolg des Eingriffs beeinflusst.

Costims – das nächste heiße Ding in der Krebstherapie?

28.05.2024 Onkologische Immuntherapie Nachrichten

„Kalte“ Tumoren werden heiß – CD28-kostimulatorische Antikörper sollen dies ermöglichen. Am besten könnten diese in Kombination mit BiTEs und Checkpointhemmern wirken. Erste klinische Studien laufen bereits.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.